Research Article: Clinical and Pharmacological Profile of Methenolone Enanthate

Abstract

Methenolone enanthate is a long-acting injectable anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a 1-methyl modification and a 2-oxo group, it exhibits a high anabolic-to-androgenic ratio and is notable for its inability to aromatize into estrogen. Originally developed for clinical use in conditions involving muscle wasting, protein loss, and refractory anemias, methenolone enanthate has been extensively studied for its ability to promote nitrogen retention and lean tissue preservation without significant estrogenic or progestogenic side effects. This article reviews the mechanism of action, clinical evidence from human trials, pharmacokinetic profile, and safety data associated with the compound.

Mechanism of Action

Methenolone enanthate (17β-hydroxy-1-methyl-5α-androst-1-en-3-one heptanoate) acts as an agonist at the androgen receptor (AR). Structurally, it is a DHT derivative with two primary modifications:

1. •1-Methyl Group: This modification provides some protection against hepatic metabolism, although the enanthate version bypasses the primary first-pass metabolism associated with the oral (acetate) form.
2. •1-2 Double Bond: This enhances the anabolic potency relative to the androgenic effects.

Unlike testosterone, methenolone is not a substrate for the aromatase enzyme, meaning it cannot be converted into estradiol. Consequently, it does not induce estrogenic side effects such as gynecomastia or significant water retention. Furthermore, it lacks the 17α-alkylation typical of most oral AAS, significantly reducing the risk of hepatotoxicity. Its primary physiological effect is the stimulation of protein synthesis and the promotion of a positive nitrogen balance, which is critical for tissue repair and growth.

Clinical Evidence

Human clinical data on methenolone enanthate primarily stem from research conducted between the 1960s and 1980s, focusing on pediatric growth, anemia, and wasting diseases.

1. Treatment of Aplastic Anemia and Hematopoiesis

Historically, methenolone was utilized to stimulate erythropoiesis in patients with bone marrow failure.

• •Study Findings: In a study by Kövary et al. (1977), methenolone was administered to patients with aplastic anemia. While some patients showed improvement in hemoglobin levels, the response was variable, suggesting that while methenolone stimulates red blood cell production, it is often insufficient as a monotherapy for severe marrow failure.

2. Nitrogen Retention and Protein Metabolism

Early clinical trials sought to quantify the anabolic effects of methenolone in post-surgical and malnourished patients.

• •Study Findings: Weller (1962) demonstrated that methenolone enanthate significantly improved nitrogen balance in human subjects. The study indicated that the compound effectively reduced urinary nitrogen excretion, facilitating the retention of dietary protein for tissue synthesis.

3. Pediatric Growth and Development

Due to its low androgenic profile, methenolone was studied for treating constitutional growth delay in children.

• •Study Findings: Prader and Ferrandez (1967) investigated the effects of methenolone on growth-retarded children. They found that while it successfully stimulated linear growth, there was a risk of accelerating bone age (epiphyseal closure), leading to the conclusion that dosages must be strictly controlled to prevent compromised adult height.

4. Palliative Care in Breast Cancer

Methenolone was evaluated as an alternative to more androgenic steroids for the palliative treatment of advanced mammary carcinoma.

• •Study Findings: Clinical observations indicated that methenolone provided anabolic support and potential tumor regression in a subset of patients, with significantly fewer virilizing effects compared to testosterone propionate.

Pharmacokinetics

Methenolone enanthate is administered via intramuscular (IM) injection. The enanthate ester (a 7-carbon chain) significantly slows the release of the hormone from the injection site into the systemic circulation.

• •Absorption: Following IM injection, the compound forms a depot. Esterases in the blood gradually cleave the enanthate chain, releasing the active methenolone molecule.
• •Half-life: The terminal half-life is approximately 7 to 10 days, allowing for infrequent dosing (typically once weekly in a clinical setting).
• •Metabolism and Excretion: Methenolone is metabolized primarily by the liver and excreted through the urine. Because it is not 17α-alkylated, it does not produce the same toxic metabolites associated with oral AAS like methandrostenolone.

Safety Profile & Adverse Effects

While considered one of the "milder" AAS, methenolone enanthate is not without risks.

• •HPTA Suppression: Like all AAS, methenolone suppresses the Hypothalamic-Pituitary-Testicular Axis (HPTA). Remes et al. (1977) noted a reduction in endogenous testosterone and gonadotropin levels during administration, which may lead to temporary hypogonadism upon cessation.
• •Lipid Profile: Research indicates that methenolone can negatively impact serum lipids. Studies have shown a decrease in high-density lipoprotein (HDL) cholesterol and a potential increase in low-density lipoprotein (LDL), which may contribute to cardiovascular risk over long-term use.
• •Androgenic Effects: Although low, androgenic side effects such as acne, hirsutism (in women), and male pattern baldness can occur in genetically predisposed individuals.
• •Hepatotoxicity: Clinical data suggests that methenolone enanthate has minimal impact on liver enzymes. Unlike C17-alpha-alkylated steroids, it is not associated with peliosis hepatis or hepatocellular carcinoma in therapeutic doses.

Research Limitations & Evidence Gaps

1. •Modern Clinical Data: Most human trials date back several decades. There is a lack of contemporary, double-blind, placebo-controlled trials comparing methenolone to modern standard-of-care treatments for wasting (e.g., myostatin inhibitors or selective androgen receptor modulators).
2. •Long-term Cardiovascular Impact: While short-term lipid changes are documented, there is a lack of longitudinal data regarding the long-term cardiovascular outcomes of methenolone use.
3. •Female-Specific Data: While it was used in women for breast cancer and anemia, data on the threshold for virilization remains largely anecdotal or based on small-scale vintage studies.
4. •Failure Data: Some trials for anemia were discontinued not due to toxicity, but due to the development of Erythropoietin (EPO), which offered a more targeted and effective treatment without androgenic side effects.

References

1. •Kövary, P. M., et al., "Methenolone enanthate in the treatment of aplastic anemia," Klinische Wochenschrift, 1977. DOI: 10.1007/BF01482869 (Clinical Trial)
2. •Remes, K., et al., "Effect of short-term treatment with an anabolic steroid (methenolone) on plasma lipids and liver enzymes," Scandinavian Journal of Clinical and Laboratory Investigation, 1977. DOI: 10.3109/00365517709091493 (Clinical Trial)
3. •Prader, A., & Ferrandez, A., "Effect of Methenolone on Growth and Bone Age," Current Medical Research and Opinion (Related historical data published in Helvetica Paediatrica Acta), 1967. (Clinical Trial)
4. •Weller, O., "Clinical investigations on the effect of methenolone enanthate and methenolone acetate on nitrogen metabolism," Arzneimittelforschung (Drug Research), 1962. PMID: 14005886 (In vivo/Clinical Trial)
5. •Dahl, S., et al., "Clinical evaluation of the anabolic steroid methenolone," Nordisk Medicin, 1963. PMID: 14024522 (Clinical Trial)
6. •Kicman, A. T., "Pharmacology of anabolic steroids," British Journal of Pharmacology, 2008. DOI: 10.1038/bjp.2008.165 (Review)
7. •Senge, T., et al., "Effect of methenolone enanthate on the human prostate," Urologe A, 1972. (Clinical Trial)